Document Detail


Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.
MedLine Citation:
PMID:  18384519     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: It remains unclear how we can shorten the treatment duration of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C virus (HCV) genotype 2 infection who achieved a rapid virological response (RVR). AIM: We compared the efficacy of antiviral combination therapy with peginterferon and ribavirin for 8 vs. 24 weeks for the treatment of patients with HCV genotype 2 infection and with RVR. METHODS: Sixty-one patients were enrolled. Serum HCV RNA was not detected at 4 weeks after the start of treatment in 32 patients with an RVR. These 32 patients were randomly assigned to 8-week (n=15) or 24-week (n=17) treatment regimens. Patients in the 8-week group who relapsed underwent a 24-week retreatment. RESULTS: No significant difference in patient characteristics was observed between the 8- and the 24-week treatment groups. A sustained virological response (SVR) was seen in five of 15 patients (33.3%) in the 8-week treatment group and 14 of 17 (82.4%) in the 24-week treatment group; the rate was significantly higher in the 24-week treatment group (P=0.0140). Nine of 10 relapsed patients in the 8-week treatment group underwent a 24-week retreatment, and seven achieved an SVR. CONCLUSION: An 8-week regimen of combination antiviral therapy with peginterferon and ribavirin yielded an increase in the relapse rate, indicating the limitation of a reduction of treatment below 12 weeks in patients with genotype 2, after RVR.
Authors:
Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Yasuhiro Sone; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Hiroyuki Atsumi; Satoshi Nakano; Takahiro Arakawa
Related Documents :
17151339 - Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset ...
11262659 - Efficacy of interferon alfa-2a in severe and refractory uveitis associated with behçet...
9836109 - Efficacy of high dose of recombinant alpha 2b interferon on long term response in chron...
2110199 - Lack of suppression of ige production by recombinant interferon gamma: a controlled tri...
2792319 - Bone marrow morphology during alpha-interferon treatment in hairy cell leukemia.
10721659 - Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report...
24326289 - Impact of the international nosocomial infection control consortium (inicc) multidimens...
22744589 - Late results of surgical treated scoliosis with the use of selective and extend instrum...
9448879 - Inappropriate sinus tachycardia (ist): management by radiofrequency modification of sin...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial     Date:  2008-04-01
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  29     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-05     Completed Date:  2009-03-09     Revised Date:  2009-04-26    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  120-5     Citation Subset:  IM    
Affiliation:
Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan. tkumada@he.mirai.ne.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antiviral Agents / administration & dosage,  pharmacology,  therapeutic use*
Drug Therapy, Combination
Female
Hepacivirus / drug effects,  genetics*
Hepatitis C, Chronic / drug therapy*,  genetics
Humans
Interferon Alfa-2a / administration & dosage,  pharmacology,  therapeutic use*
Male
Middle Aged
Polyethylene Glycols / administration & dosage,  pharmacology,  therapeutic use*
Ribavirin / administration & dosage,  pharmacology,  therapeutic use*
Statistics, Nonparametric
Viremia
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Polyethylene Glycols; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; 76543-88-9/Interferon Alfa-2a

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Aspergillus nidulans FcyB cytosine-purine scavenger is highly expressed during germination and i...
Next Document:  Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C...